24,452 reports of this reaction
5.9% of all PANTOPRAZOLE SODIUM reports
#1 most reported adverse reaction
CHRONIC KIDNEY DISEASE is the #1 most commonly reported adverse reaction for PANTOPRAZOLE SODIUM, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 24,452 FDA adverse event reports linking PANTOPRAZOLE SODIUM to CHRONIC KIDNEY DISEASE. This represents approximately 5.9% of all 411,823 adverse event reports for this drug.
PANTOPRAZOLE SODIUM has an overall safety score of 85 out of 100. Patients taking PANTOPRAZOLE SODIUM who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC KIDNEY DISEASE is moderately reported among PANTOPRAZOLE SODIUM users, representing a notable but not dominant share of adverse events.
In addition to chronic kidney disease, the following adverse reactions have been reported for PANTOPRAZOLE SODIUM:
The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:
CHRONIC KIDNEY DISEASE has been reported as an adverse event in 24,452 FDA reports for PANTOPRAZOLE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC KIDNEY DISEASE accounts for approximately 5.9% of all adverse event reports for PANTOPRAZOLE SODIUM, making it one of the most commonly reported side effect.
If you experience chronic kidney disease while taking PANTOPRAZOLE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.